Skip to content
2000
Volume 23, Issue 6
  • ISSN: 1570-1611
  • E-ISSN: 1875-6212

Abstract

Introduction

Current guidelines and consensus statements advise caution in using direct oral anticoagulants (DOACs) for morbidly obese patients with body mass index (BMI) >40 kg/m2, indicating warfarin as the most studied treatment.

Methods

We systematically searched databases from their inception to January 4, 2024, to identify studies that evaluated the effectiveness and safety of DOACs compared to warfarin in patients with BMI >40 kg/m2 and atrial fibrillation (AF) or venous thromboembolism (VTE). The outcomes of all-cause mortality, major and minor bleeding, stroke/systematic embolism (SE), VTE, and their composite endpoint were analyzed using a random-effects model.

Results

This meta-analysis included 24 studies and 119,960 morbidly obese patients with AF or VTE on oral anticoagulation therapy: 51,363 on DOACs (43%) . (57%) 68,597 on warfarin. DOAC use was significantly associated with lower all-cause mortality and major bleeding risk compared to warfarin. Although the risk of composite endpoint, stroke/SE, and VTE was lower in the DOAC group, no statistically significant difference was observed, indicating no superiority of warfarin compared to DOAC use. The risk of minor bleeding events, hemorrhagic stroke, and ischemic stroke was lower in the DOAC compared to the warfarin group. The same trend favoring DOACs over warfarin in all assessed endpoints was observed in the subgroup analysis based on anticoagulation indication (AF or VTE).

Conclusion

Our findings have documented a potentially more effective and safer profile of DOACs compared to warfarin in morbidly obese patients regardless of the indication for anticoagulation.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611330090250130075810
2025-11-01
2025-12-24

  • From This Site

    /content/journals/cvp/10.2174/0115701611330090250130075810
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LavieC.J. ArenaR. AlpertM.A. MilaniR.V. VenturaH.O. Management of cardiovascular diseases in patients with obesity.Nat. Rev. Cardiol.2018151455610.1038/nrcardio.2017.108 28748957
     [Google Scholar]
  2. GoossensG.H. The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function.Obes. Facts201710320721510.1159/000471488 28564650
     [Google Scholar]
  3. KunutsorS.K. Obesity or adipokines—which should be targeted for venous thromboembolism prevention?J. Thromb. Haemost.202321219519710.1016/j.jtha.2022.11.008 36775413
     [Google Scholar]
  4. MahajanR. LauD.H. BrooksA.G. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity.J. Am. Coll. Cardiol.201566111110.1016/j.jacc.2015.04.058 26139051
     [Google Scholar]
  5. KoskinasK.C. CraenenbroeckV.E.M. AntoniadesC. Obesity and cardiovascular disease: An ESC clinical consensus statement.Eur. Heart J.202445384063409810.1093/eurheartj/ehae508 39210706
     [Google Scholar]
  6. KalaniC. AwudiE. AlexanderT. UdeaniG. SuraniS. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.Hosp. Pract.201947418118510.1080/21548331.2019.1674586 31580732
     [Google Scholar]
  7. ReillyP.A. LehrT. HaertterS. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).J. Am. Coll. Cardiol.201463432132810.1016/j.jacc.2013.07.104 24076487
     [Google Scholar]
  8. MartinK. WestendorfB.J. DavidsonB.L. HuismanM.V. SandsetP.M. MollS. Use of the direct oral anticoagulants in obese patients: Guidance from the SSC of the ISTH.J. Thromb. Haemost.20161461308131310.1111/jth.13323 27299806
     [Google Scholar]
  9. KearonC. AklE.A. OrnelasJ. Antithrombotic therapy for VTE disease.Chest2016149231535210.1016/j.chest.2015.11.026 26867832
     [Google Scholar]
  10. PhillippeH.M. WrightB.M. BowermanK.E. AndrusM.R. Pharmacist interventions regarding the appropriateness of apixaban, rivaroxaban, dabigatran, and warfarin in a university-affiliated outpatient clinic.J. Pharm. Technol.201632245252
     [Google Scholar]
  11. PageM.J. McKenzieJ.E. BossuytP.M. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.Syst. Rev.20211018910.1186/s13643‑021‑01626‑4 33781348
     [Google Scholar]
  12. HicksK.A. MahaffeyK.W. MehranR. 2017 Cardiovascular and stroke endpoint definitions for clinical trials.Circulation2018137996197210.1161/CIRCULATIONAHA.117.033502 29483172
     [Google Scholar]
  13. SpyropoulosA.C. AshtonV. ChenY.W. WuB. PetersonE.D. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.Thromb. Res.201918215916610.1016/j.thromres.2019.08.021 31493618
     [Google Scholar]
  14. PeralesI.J. AgustinS.K. DeAngeloJ. CampbellA.M. Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight.Ann. Pharmacother.202054434435010.1177/1060028019886092 31672028
     [Google Scholar]
  15. FalkK. McCombM.N. ShapiroN.L. UppuluriE.M. Prescribing pattern of oral anticoagulants in patients with obesity.J. Pharm. Pract.202235224825510.1177/0897190020969276 33138664
     [Google Scholar]
  16. KushnirM. ChoiY. EisenbergR. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: A single-centre, retrospective analysis of chart data.Lancet Haematol.201967e359e36510.1016/S2352‑3026(19)30086‑9 31133411
     [Google Scholar]
  17. WeirM.R. ChenY.W. HeJ. BookhartB. CampbellA. AshtonV. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes.J Diab Compl2021351110802910.1016/j.jdiacomp.2021.108029 34538715
     [Google Scholar]
  18. KidoK. NgorsurachesS. Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation.Ann. Pharmacother.201953216517010.1177/1060028018796604 30130979
     [Google Scholar]
  19. PetersonE.D. AshtonV. ChenY.W. WuB. SpyropoulosA.C. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.Am. Heart J.201921211311910.1016/j.ahj.2019.02.001 30981035
     [Google Scholar]
  20. CrouchA. NgT.H. KelleyD. KnightT. EdwinS. GiulianoC. Multi‐center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.Pharmacotherapy202242211913310.1002/phar.2655 34904263
     [Google Scholar]
  21. CohenA.T. PanS. ByonW. IlyasB.S. TaylorT. LeeT.C. Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: Insights from amplify.Adv. Ther.20213863003301810.1007/s12325‑021‑01716‑8 33890242
     [Google Scholar]
  22. CostaO.S. WestendorfB.J. AshtonV. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: Analysis of electronic health record data.J. Thromb. Thrombolysis202151234935810.1007/s11239‑020‑02199‑0 32588288
     [Google Scholar]
  23. AlbertsM.J. HeJ. KharatA. AshtonV. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy.Am. J. Cardiovasc. Drugs202222442543610.1007/s40256‑021‑00520‑7 35092000
     [Google Scholar]
  24. CohenA. SahJ. LeeT. Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity.J. Clin. Med.202110220010.3390/jcm10020200 33429844
     [Google Scholar]
  25. BriasoulisA. MentiasA. MazurA. AlvarezP. LeiraE.C. ghan Sarrazin VMS. Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation.Cardiovasc. Drugs Ther.202135226127210.1007/s10557‑020‑07126‑2 33404923
     [Google Scholar]
  26. PerinoA.C. FanJ. SchmittS. Anticoagulation treatment and outcomes of venous thromboembolism by weight and body mass index: Insights from the veterans health administration.Circ. Cardiovasc. Qual. Outcomes20211411e00800510.1161/CIRCOUTCOMES.121.008005 34724801
     [Google Scholar]
  27. BarakatA.F. JainS. MasriA. Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories.JACC Clin. Electrophysiol.20217564965810.1016/j.jacep.2021.02.002 33812834
     [Google Scholar]
  28. PatilT. LebrechtM. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population.Thromb. Res.202019212413010.1016/j.thromres.2020.04.015 32473496
     [Google Scholar]
  29. WeaverP. NgT.H. BreedenT. EdwinS.B. HaanB. GiulianoC. Management of venous thromboembolism in morbid obesity with rivaroxaban or warfarin.Ann. Pharmacother.202256121315132410.1177/10600280221089008 35505606
     [Google Scholar]
  30. AlotaibiS.N. HasanH. MetwaliH. AseeriM. Comparing the efficacy and safety of apixaban versus warfarin in morbidly obese patients.Cureus20221410e3030310.7759/cureus.30303 36407232
     [Google Scholar]
  31. LorenzM.A. LinnemanT.W. Comparing safety and efficacy of direct oral anticoagulants versus warfarin in extreme obesity.J. Pharm. Pract.20233661375138210.1177/08971900221116809 35938580
     [Google Scholar]
  32. BiancoC. WenS. CaiY. FinchC. KimbleW. CaccamoM. Novel oral anticoagulants are safe and effective for thromboembolic prophylaxis in obese patients with atrial fibrillation. J Amer College Coll. Cardiol.20207511505
     [Google Scholar]
  33. MartinK.A. LanckiN. LiC. DOAC compared with warfarin for VTE in patients with obesity: A retrospective cohort study conducted through the VENUS network.J. Thromb. Thrombolysis202355468569010.1007/s11239‑023‑02774‑1 36757644
     [Google Scholar]
  34. PilkertonC.S. AdelmanM. CrocettiE. XiangJ. StrickV. PonteC.D. Direct oral anticoagulants: Probability of recurrent venous thromboembolism and bleeding risk in an obese population.Ann. Pharmacother.2023588781789 37994550
     [Google Scholar]
  35. HattawayQ. StarrJ.A. PinnerN.A. Direct oral anticoagulants for the treatment of venous thromboembolism in obesity.J. Pharm. Technol.202339626927310.1177/87551225231196748 37974596
     [Google Scholar]
  36. MartinK.A. WestendorfB.J. DavidsonB.L. HuismanM.V. SandsetP.M. MollS. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC subcommittee on control of anticoagulation.J. Thromb. Haemost.20211981874188210.1111/jth.15358 34259389
     [Google Scholar]
  37. ZhaoY. GuoM. LiD. Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: An updated literature review.Clin. Appl. Thromb. Hemost.2023291076029623115363810.1177/10760296231153638 36760080
     [Google Scholar]
  38. JoglarJ.A. ChungM.K. ArmbrusterA.L. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.Circulation20241491e1e15610.1161/CIR.0000000000001193 38033089
     [Google Scholar]
  39. KubitzaD. BeckaM. ZuehlsdorfM. MueckW. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.J. Clin. Pharmacol.200747221822610.1177/0091270006296058 17244773
     [Google Scholar]
  40. FryarC. CarrollM. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. NCHS Health E-Stats.202217
     [Google Scholar]
  41. WangT.J. PariseH. LevyD. Obesity and the risk of new-onset atrial fibrillation.JAMA2004292202471247710.1001/jama.292.20.2471 15562125
     [Google Scholar]
  42. HuxleyR.R. LopezF.L. FolsomA.R. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The atherosclerosis risk in communities (ARIC) study.Circulation2011123141501150810.1161/CIRCULATIONAHA.110.009035 21444879
     [Google Scholar]
  43. HolstA.G. JensenG. PrescottE. Risk factors for venous thromboembolism: Results from the copenhagen city heart study.Circulation2010121171896190310.1161/CIRCULATIONAHA.109.921460 20404252
     [Google Scholar]
  44. SamamaM.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The sirius study.Arch. Intern. Med.2000160223415342010.1001/archinte.160.22.3415 11112234
     [Google Scholar]
  45. AgenoW. BecattiniC. BrightonT. SelbyR. KamphuisenP.W. Cardiovascular risk factors and venous thromboembolism: A meta-analysis.Circulation200811719310210.1161/CIRCULATIONAHA.107.709204 18086925
     [Google Scholar]
  46. SagrisM. KokkinidisD.G. LempesisI.G. Nutrition, dietary habits, and weight management to prevent and treat patients with peripheral artery disease.Rev. Cardiovasc. Med.202021456557510.31083/j.rcm.2020.04.202 33388001
     [Google Scholar]
  47. ChopardR. AlbertsenI.E. PiazzaG. Diagnosis and treatment of lower extremity venous thromboembolism.JAMA2020324171765177610.1001/jama.2020.17272 33141212
     [Google Scholar]
  48. SandhuR.K. EzekowitzJ. AnderssonU. The ‘obesity paradox’ in atrial fibrillation: Observations from the aristotle (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.Eur. Heart J.201637382869287810.1093/eurheartj/ehw124 27071819
     [Google Scholar]
  49. PatelM.R. MahaffeyK.W. GargJ. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N. Engl. J. Med.20113651088389110.1056/NEJMoa1009638 21830957
     [Google Scholar]
  50. CoonsJ.C. AlbertL. BejjaniA. IasellaC.J. Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism.Pharmacotherapy202040320421010.1002/phar.2369 31968126
     [Google Scholar]
  51. ThangjuiS. KewcharoenJ. YodsuwanR. Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: Systematic review and meta-analysis.Eur. Heart J. Cardiovasc. Pharmacother.20228432533510.1093/ehjcvp/pvab026 33730164
     [Google Scholar]
  52. MhannaM. BeranA. AbdouhA.A. Direct oral anticoagulants versus warfarin in morbidly obese patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis.Am. J. Ther.2021285e531e53910.1097/MJT.0000000000001403 34491953
     [Google Scholar]
  53. PatelS.M. BraunwaldE. SteffelJ. Efficacy and safety of non–vitamin-k antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and body weight: An individual patient data meta-analysis of 4 randomized clinical trials of patients with atrial fibrillation.Circulation20241491293294310.1161/CIRCULATIONAHA.123.066279
     [Google Scholar]
  54. EeS.C.E. RosarioB.H. MokZ.H. TunM.H. RazaliS.S.B.Y. TanB.H. Warfarin versus direct oral anticoagulants in South Asian octogenarians: A retrospective review.Blood Coagul. Fibrinolysis202334531932610.1097/MBC.0000000000001233 37395223
     [Google Scholar]
  55. KanaanD.M. MalloyR. KnowlesD. Evaluation of patient characteristics linked to major bleeding events in patients prescribed direct oral anticoagulants.Clin. Appl. Thromb. Hemost.2023291076029623117276510.1177/10760296231172765 37246422
     [Google Scholar]
  56. CeredaA. LucreziottiS. FranchinaA.G. Systematic review and meta-analysis of oral anticoagulant therapy in atrial fibrillation cancer patients.Cancers 2023159257410.3390/cancers15092574 37174043
     [Google Scholar]
/content/journals/cvp/10.2174/0115701611330090250130075810
Loading
Comparative Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Morbidly Obese Patients (BMI \>40 kg/m2): A Systematic Review and Meta-Analysis
Curr. Vasc. Pharmacol. 23, 404 (2025); https://doi.org/10.2174/0115701611330090250130075810
/content/journals/cvp/10.2174/0115701611330090250130075810
/content/journals/cvp/10.2174/0115701611330090250130075810
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article. PPRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): anticoagulation; atrial fibrillation; Direct oral anticoagulants; morbidly obese; venous thromboembolism; vitamin-K antagonist; warfarin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test